Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ATM R1882* |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ATM R1882* | gastroesophageal adenocarcinoma | predicted - sensitive | Capecitabine + Oxaliplatin | Case Reports/Case Series | Actionable | In a retrospective analysis, treatment with the combination of Xeloda (capecitabine) and Eloxatin (oxaliplatin) resulted in a partial response and a progression-free survival of 12.3 months in a patient with gastroesophageal adenocarcinoma harboring ATM R1882* (PMID: 37129948). | 37129948 | |
| ATM R1882* | Advanced Solid Tumor | sensitive | Olaparib | Olaparib | Preclinical - Cell culture | Actionable | In a preclinical study, treatment with Lynparza (olaparib) inhibited survival and proliferation of cells expressing ATM R1882* in a high-throughput cell culture assay (PMID: 40580951). | 40580951 |